drugset
drugset / Trial / NCT02262364

Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)

NCT02262364 ↗

Phase 1 Completed 11 enrolled Zimmer Biomet Biomet Biologics, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the safety of a single injection of APS.

Timeline

Start
2014-11
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject APS Protein / enzyme biologic — Other

Indications

osteoarthritis, knee